The stock closed at 11.43 DKK, down 0.4% on Friday. CEO Ulrich Krasilnikoff began with a brief introduction to the company, followed by an engaging overview of the growth potential within Nuclear Medicine. He focused on the two key areas relevant to Curasight - treatment (uTREAT) and diagnostics (uTRACE). There is large interest from major pharmaceutical companies in this field, as highlighted by the increased M&A activity in the segment.  Among these, CEO Ulrich Krasilnikoff mentioned Novartis’ acquisition of Mariana Oncology and Bristol-Myers Squibb’s (BMS) purchase of RayzeBio. The number of transactions in 2024 has already surpassed those in 2023. I refer to the attached slide for insights into market growth: CSO Andreas Kjær elaborated on the significance of the recently published uTRACE Phase 2 data in the EJNMMI Research journal. He also explained why Curasight has chosen GBM as the “proof-of-concept” candidate for the uTREAT study. For more details, read our latest update here: Update regarding uTRACE phase 2 study   Curasight’s platform, based on the uPAR biomarker, is cancer-specific but not cancer-type specific. There is a clear correlation between the aggressiveness of the cancer and the amount of uPAR expressed. Currently, approximately 50% of all cancer patients undergo radiation therapy, which often damages healthy tissue along with the tumor. Curasight’s theranostic platform offers a groundbreaking solution: it illuminates the tumor and its metastases and delivers targeted radiation from within, significantly reducing damage to healthy tissue. Every year, there are 65,000 new cases of brain cancer in the EU and the US, 30,000 of which are high-grade gliomas—the primary market for Curasight. This disease primarily affects middle-aged adults and children, with a very high mortality rate. Current treatments rely mainly on radiation therapy and chemotherapy, with no significant innovations in this field for decades. Below is a detailed timeline for the “Proof-of-Concept” uTREAT study: Finanlly the exercise period for Curasight’s TO1 warrants begins on November 21, 2024, and ends on December 5, 2024. The exercise price will be based on the VWAP20 with a 30% discount, within a range of DKK 11.50-15.55. Full utilization of the warrants could provide the company with up to DKK 57.5 million. Listen to the full interview here: Deep Dive Brain cancer Disclaimer: HC Andersen Capital receives payment from Curasight as part of a DigitalIR/Corporate Visibility and IR advisory agreement.Claus Thestrup, November 18, 2024, at 09:05.

info@inderes.fi (inderes.fi)

© Inderes Oyj. All rights reserved.